Tachyarrhythmia
|
AVID TRIAL: ICD vs. Antiarrhythmic Drug Treatment for VF or Sustained VT1
Protocol:
Hypothesis:
To determine whether initial treatment strategy of ICD or antiarrhythmic drug therapy results in longer life.
Primary endpoint:
Total mortality
Secondary endpoints:
Cost and quality of life
Status:
Start: 1993
Completion: 1997
Sample size: Planned - 2,500
At Termination - 1,016
Results:
Study was terminated early due to significant results (see above).
The ICD group experienced a 39% reduction in deaths in the first year, with a 27% and 31% reduction in years two and three.
"If we apply the results of AVID to the population at risk [350,000], over 1,000 lives would be saved each year in the U.S."
Dr. Claude Lenfant,
National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health
References
- The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med.
Secondary Prevention Trials
Additional Information
|
©Medtronic, Inc. 2008 • Contact Medtronic • Privacy Statement • Terms of Use • Site Map